Navigation Links
New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer
Date:5/31/2008

d safety of TORISEL for the treatment of advanced RCC patients. Wyeth is committed to the continued exploration of mTOR inhibition with TORISEL for the treatment of a variety of cancers," says Joseph S. Camardo, M.D., Senior Vice President, Global Medical Affairs, Wyeth Pharmaceuticals.

Abstract 5050: Exploratory Analysis of the Influence of Nephrectomy Status on Temsirolimus Efficacy in Patients With Advanced Renal Cell Carcinoma and Poor-Risk Features

This retrospective subgroup analysis evaluated whether the nephrectomy status (whether or not patients had undergone surgery for removal of the affected kidney) of patients with advanced RCC enrolled in the pivotal phase 3 study had an effect on the observed overall survival benefit of TORISEL compared with interferon-alpha. Investigators determined that both overall survival and progression-free survival were longer for patients treated with TORISEL compared with those treated with interferon-alpha, regardless of whether they had undergone nephrectomy. In addition, among patients who had not undergone nephrectomy, more patients treated with TORISEL showed reductions in the size of their primary kidney tumor than those treated with interferon-alpha (58% vs. 31%).

Abstract 5116: Characterization of Hyperglycemia, Hypercholesterolemia and Hyperlipidemia in Patients With Advanced Renal Cell Carcinoma Treated With Temsirolimus or Interferon-Alpha

Another analysis presented at the ASCO meeting examined specific side effects seen in the pivotal phase 3 study of TORISEL for advanced RCC, including high levels of blood glucose (hyperglycemia), cholesterol (hypercholesterolemia), and lipids (hyperlipidemia). More patients treated with TORISEL, either with or without diabetes, developed hyperglycemia of grade 2 or higher (P=0.002 for diabetic patients, P=0.001 for non-diabetic patients), compared with those treated with interferon-alpha. TORISEL also was associated with the development of hyperchole
'/>"/>

SOURCE Wyeth Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. New MIRCERA(R) Data Analyses to be Featured at the American Society of Nephrology Annual Meeting
2. New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG
3. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
4. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
5. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
6. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
7. Data To Be Presented at ASCO Supports Potential of Peregrines Cotara(R) for the Treatment of Brain Cancer
8. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
9. Two DOXIL(R) Studies to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
10. Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration
11. Safety and Efficacy Results Presented From Largest Prospective Controlled Clinical Study of Ulcerative Colitis

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...RK,Nov.25/PRNewswire/--Reportlinker.comannouncesth...e: ,, IntranasalDrugDelivery-USMarketTrends&am...ntranasal-Drug-Delivery---US-Market-Trends--Analys...witnessinganexpansionoftherapeuticapplicationsfrom...edeliveryofsystemictherapeuticdrugs.Thefutureofthe...
(Date:11/25/2009)...AINVIEW,Calif.,Nov.25/PRNewswire/-- ChemoCentryx,...theCompany,sPROTECT-1(theProspectiveRandomizedOral...EN(TM)(CCX282-B)inpatientswithmoderate-to-severeCr...ablesafetyandtolerabilityprofile.Thestudydemonstra...seseverityasdefinedasa70-pointdecreaseintheCrohn,s...
(Date:11/24/2009)...E,Calif.,Nov.24/PRNewswire-FirstCall/--Endologix,I...atmentsforaorticdisorders,announcedtodaythatithasf...epatentinfringementlawsuitbroughtagainstitinOctobe...DistrictCourtinIndianapolis,Indiana. ,, Endolog...tedStatesPatentandTrademarkOffice(USPTO)conductspr...
Breaking Medicine Technology:Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 2Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 4Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 5ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement 2Reportlinker Adds Novo Nordisk A S 3A PharmaVitae Profile 58967 1Reportlinker Adds Novo Nordisk A S 3A PharmaVitae Profile 58967 2Reportlinker Adds Novo Nordisk A S 3A PharmaVitae Profile 58967 3Reportlinker Adds Novo Nordisk A S 3A PharmaVitae Profile 58967 4Reportlinker Adds Novo Nordisk A S 3A PharmaVitae Profile 58967 5Autism Stats Exaggerated 3A Parents Pushing Back This Weekend 58962 1Autism Stats Exaggerated 3A Parents Pushing Back This Weekend 58962 2Integrated Benefits Institute Announces Availability of 2008 IBI Benchmarking Industry Reports 58957 1Integrated Benefits Institute Announces Availability of 2008 IBI Benchmarking Industry Reports 58957 2Integrated Benefits Institute Announces Availability of 2008 IBI Benchmarking Industry Reports 58957 3
...utics,Inc. (CTI) (Nasdaq: CTIC ; MTA) today annou... accepted for review CTI,s Marketing Authorization...glumex, CT-2103) for,first-line treatment of patie...COG (Eastern Cooperative Oncology Group) performan...ginning of March. The validation of the MAA,for XY...
...ics, Inc.,(Nasdaq: CVTX ) today announced new dat... of the American College of Cardiology shows that,...gnificantly reduced the,risk of recurrent ischemia...fication of antianginal therapy (p=0.009) in angin..., Additionally, Ranexa significantly improved all...
Other Medicine Technology:European Regulatory Agency Accepts Cell Therapeutics, Inc.'s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review 2European Regulatory Agency Accepts Cell Therapeutics, Inc.'s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review 3European Regulatory Agency Accepts Cell Therapeutics, Inc.'s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review 4CV Therapeutics' Anti-Ischemic Therapy Ranexa(R) Significantly Reduces Cardiac Chest Pain Symptoms and Recurrent Ischemia in MERLIN-TIMI 36 Patients With Angina 2CV Therapeutics' Anti-Ischemic Therapy Ranexa(R) Significantly Reduces Cardiac Chest Pain Symptoms and Recurrent Ischemia in MERLIN-TIMI 36 Patients With Angina 3
(Date:11/25/2009)...as too short to draw definite conclusions, experts... News) -- In diabetic patients with blocked corona...outcomes at one year whether patients undergo bypa...esearchers report. , Bypass surgery has been th...ronary artery disease. However, less invasive appr...
(Date:11/25/2009)...ees few signs of trouble with the H1N1 vaccine, ,...- The ongoing H1N1 swine flu pandemic may be drivi...unger patients, a U.S. health official said Wednes...eumococcal infections around the country," Dr. Ann...munization and Respiratory Diseases at the U.S. Ce...
(Date:11/25/2009)...ectal cancer also can reverse a rare stomach disor...r the disease, researchers at Vanderbilt Universit...sease causes thickening of the stomach lining, sev...s anemia and swelling in the feet and ankles due t... gastric cancer. Previously, the only effective tr...
(Date:11/25/2009)...itiative expands to include cost-effective, sustai...d healthcare professionals in developing world. ,...vember 25, 2009 -- Elluminate, Inc. , the leader ...ons that support 21st century teaching, learning,... and Ice initiative was awarded iNACOL,s first-e...
(Date:11/25/2009)...PRNewswire/--dazzlesmile,llc www.dazzlesmile.com a...e.com havefileda67-pagefederallawsuitagainstEpicAd...lms,FarendServicesLimited,andAtLastFulfillment.The...CourtfortheDistrictofUtah,allegesmassivenationalco...teethwhiteningproducts,violationsoftheRacketeering...
Breaking Medicine News(10 mins):Health News:Stenting May Equal Bypass for Diabetic Heart Patients 2Health News:Stenting May Equal Bypass for Diabetic Heart Patients 3Health News:Swine Flu Tied to Rise in Pneumonias Among Young 2Health News:Swine Flu Tied to Rise in Pneumonias Among Young 3Health News:Swine Flu Tied to Rise in Pneumonias Among Young 4Health News:Vanderbilt scientists report first effective medical therapy for rare stomach disorder 2Health News:Elluminate's Fire and Ice Project Recognized as First-Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice 2Health News:Elluminate's Fire and Ice Project Recognized as First-Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice 3Health News:Elluminate's Fire and Ice Project Recognized as First-Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice 4Health News:Elluminate's Fire and Ice Project Recognized as First-Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice 5Health News:dazzlesmile Sues Epic Advertising and Jesse Willms 2
...y as it is better than sequential planning of with...ing can be easily quit// if a decision is taking i...e fruitful sometime. But the researchers at Un...ed suddenly succeeded for at least six months, com...
...s now medical colleges all set to shock parents of...ctors//. This goes for people based in Karnatak...remely high for 2006-07 session. The respite co.... The college which quoted the highest annual fee...
...Bio beer which contains various herbs and vitamins...takers, as the new beer does not increase obesity ... The beer, invented by Srinivasa Amarnath over 10...and hops. The vitamin-rich beer is five perc...
...t Therapy Unit of the University of Navarra's Ana ...nducting basic research by the Danone Institute. T...n a program// aimed at defining individualized tre...hormonal and metabolic response of women who are o...
...regard to a massive study concerning the bird flu ...t the St. Jude Children's Research Hospital. This ...egarding the proteins// and genes of these viruse... effects on the human race. The Infectious Disease...
...iversity of Pittsburgh said that they have genetic...contains the components of the deadly strain H5N1....ete protection to mice and chickens from infection...d in cells and very easily produced in large amoun...
Other Medicine News:Health News:Vaccine to protect birds against avian flu, engineered 2
Mosaic
...a Windows 2000 PC based EEG with high performance ...are. EEG-9200 provides high quality performance fr...ep lab or EEG lab. Quality EEG recording is assure...ax has high performance, high sensitivity amplifie...
Neuropack MEB-9100 Series
X-SIZER Catheter System
Medicine Products: